I really don't want to be a doctor

Chapter 505 There is no unparalleled road?

However, it is a bad idea to influence GCP's review through others.

Jing Xiaoran still has second-hand preparations!
FDA, the Food and Drug Administration of the United States, is the highest law enforcement agency specializing in food and drug management.

While Shenzhou Lab applied for Huaxia GCP review, it also applied for US FDA review at the same time.

It is much more difficult to pass the FDA review than GCP. After all, the United States is still the center of global technology.

The standards and guidelines of most industries are formulated and issued by the United States.

At present, although the immune checkpoint inhibitors of Shenzhou Laboratory have encountered a lot of difficulties in the GCP review.

But if it can successfully pass the review of the US FDA, it can definitely put pressure on GCP in turn!

If a drug can pass the FDA review, it definitely far exceeds the GCP standard.

Huaxia GCP, represented by Xu Li, has no reason to continue the review and not allow the Shenzhou Laboratory to pass.

Otherwise, the credibility of the entire Huaxia GCP will be greatly reduced.

What's more, Xu Li is only a member of the GCP, and he has no absolute power to decide the life or death of a drug.

However, the difficulty of passing the FDA review is much higher than that of GCP, and it is not easy to pass the FDA review in a short time.

Jing Xiaoran thought of Pfizer!

In the United States, Jing Xiaoran's only network resource is Pfizer.

This is still relying on the accumulated contacts of "new oral anticoagulant drugs".

However, since Shenzhou Lab refused to transfer the patent of "immune checkpoint inhibitor" to Pfizer, the relationship between the two parties has fallen into a freezing point.

Harris, who used to have a good relationship with Jing Xiaoran, also had no contact with Shenzhou Lab for a long time due to the internal pressure of Pfizer.

If Pfizer can help, relying on Pfizer's influence in the United States, the possibility of Shenzhou Lab passing FDA review in a short period of time will become very high!
Jing Xiaoran listed all the risks and possibilities...

It is the best choice to cooperate with Pfizer now!

……

United States, Pfizer headquarters.

Harris is listening to his subordinates report on Pfizer's performance last quarter, especially for "new oral anticoagulants"!
"Mr. Hammer, as of the 30th of last month, the turnover of our new oral anticoagulant drug last quarter was 12 billion US dollars!"

"It has been growing for three consecutive quarters, and this quarter's growth is the last, reaching a growth rate of 20%. This is also because the entire Huaxia District has begun to pay attention to new oral anticoagulants, and all turnover has an explosive growth!"

"However, our company's turnover in other fields, such as the oncology field, is not satisfactory, and it is suppressed to death by companies such as AstraZeneca!"

"At present, there are even rumors that AstraZeneca's new anti-tumor drug-immune checkpoint inhibitors will soon be successfully developed. This is a very serious blow to Pfizer's oncology field."

"Mr. Harris, at the last meeting of the board of directors, we emphasized that our future anti-tumor planning must occupy at least 10% of the share!"

After listening to the subordinate's report, Hammer first smiled, then gradually restrained himself, and finally frowned deeply.

Pfizer's current performance in the cardiovascular field is very good, mainly due to new oral anticoagulants.

The turnover is increasing year after year!
However, in the field of oncology, Pfizer has been unable to come up with new drugs for many years, and its competitiveness is really insignificant compared with companies such as AstraZeneca.

In the field of medicine, the most profitable fields are anti-tumor and cardiovascular fields!
Businessmen are always chasing the highest interests!

Even though Pfizer is currently very successful in the cardiovascular field, they will not be satisfied and still want to extend their tentacles to the field of tumors.

As one of the five business managers of Pfizer, Hamer has a tough task.

"Modi, does the company currently have any new drugs in the field of tumor?"

Hammer looked up at the subordinate standing in front of him.

"Mr. Hamer, since the last time the board of directors cut off the immune checkpoint inhibitor project, the company has not produced any new drugs for the time being, but there are more than a dozen new drugs under development, but it is a long time before the first phase of clinical trials. Don't think about it right now!"

Modi was still very clear about the company's drugs under development, and told Hamer everything he knew.

Hammer flipped through the list of drugs under development in his hand, his brows furrowed deeper and deeper.

While the board of directors requires growth in the performance of the anti-tumor field, it does not give new research drugs.

The share of the old drugs in the past is basically the same, and it is almost impossible to achieve a large growth.

The only way is to launch a new drug!
But Pfizer doesn't have it yet!
This is really wanting the horse to run, but not to eat grass.

Hamer could only complain a few words in his heart. Since the board of directors had requested this, they just did it.

Otherwise, I will give up my position tomorrow!
"At present, there are only three ways. First, Pfizer will quickly launch a new anti-tumor drug!"

"Second, directly purchase finished patent medicines!"

"Third, get the agency rights of other companies' drugs in the United States!"

Hammer said his current plan.

When Modi heard the words, he gave a wry smile: "Mr. Hammer, for the first method, the new drug will have to wait at least three years! Three years, we can't afford to wait now!"

"The second method is that the transfer fee of the finished patented drug is high, and it is generally in the hands of a large company, so it will not be sold easily. Our company was able to acquire a new type of oral anticoagulant before. There's a second chance."

"As for the third option, it is somewhat possible. However, companies that have the strength to develop this new type of anti-tumor drug are generally large companies with their own sales teams, and do not need to entrust us as an agent. The method is also..."

This won't work, that won't work either, it's really worrying people to death!

Hamer rubbed his face vigorously with his hands, trying to calm down.

Isn't there an old saying in Huaxia that there is no unparalleled road?

There must be a way, there must be!
Hamer summoned all the employees of the sales department, informed them, and held a meeting all night, so he must come up with a solution.

U.S. time, three o'clock in the morning.

The night is deep.

Pfizer's sales department building is still brightly lit.

Some employees have already begun to doze off, and some are still typing documents in front of the computer.

Everyone didn't leave, they were all here to accompany the manager Hamer, trying to find a way to break the situation.

At this moment, a reminder of a new email suddenly appeared on the computer in front of Hammer.

Distraught, Hammer was about to turn off the message reminder, but accidentally saw that the sender of this email was Jing Xiaoran.

"Jing? What does he want me for?"

In doubt, Hammer clicked on the email.

(End of this chapter)